TNF-α-Blocker statt Steroid?

Successful Treatment of Refractory Behçet's Disease with the TNF-α Blocker Infliximab

Steroid-resistant sarcoidosis: is antagonism of TNF-α the answer?

Steroid-resistant sarcoidosis has conventionally been treated with various drugs, including methotrexate, azathioprine, cyclophosphamide, cyclosporine, antimalarial drugs and thalidomide, with variable success. There is a compelling need for more efficient and safer alternatives to these agents. Several lines of evidence suggest a critical role of TNF-α (tumour necrosis factor-α) in the initiat...

The Effect of TNF-α Blocker HL036337 and Its Best Concentration to Inhibit Dry Eye Inflammation

PURPOSE Dry eye syndrome is commonly thought of as an inflammatory disease, and we have previously presented data showing the effectiveness of topical TNF-α blocker agents for the treatment of this condition. The purpose of this study was to investigate the effectiveness of the TNF-α blocking agent HL036337 compared to cyclosporine A for the treatment of dry eye induced inflammation in order to...

successful treatment of refractory behçet's disease with the tnf-α blocker infliximab

0

Monoclonal Anti-TNF-α Antibodies for Severe Steroid-Dependent Asthma: A Case Series

BACKGROUND Refractory asthma represents an important condition, with considerable morbidity and mortality. Tumor necrosis factor α (TNF-α) is a potential target for treatment of severe asthma. However, controlled studies have shown controversial results and the risk-benefit profile of TNF-blocking agents is still debated. OBJECTIVES To describe the effect of infliximab on asthma control in pa...